Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Omecamtiv Mecarbil
Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF
Posted inCardiology Clinical Updates news

Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF

Posted by MedXY By MedXY 12/28/2025
This review synthesizes findings from the GALACTIC-HF trial regarding the efficacy and safety of omecamtiv mecarbil across age groups, highlighting its benefits in older patients and those with severe heart failure.
Read More
  • The Landscape of Late-Life Dementia: Why Mixed Neuropathologies Are the Rule, Not the Exception
  • Preparation Is Key: Study Finds Pre-Dose Therapy Hours Predict Success in Psychedelic-Assisted Therapy for Depression
  • Childhood ADHD Traits Linked to Increased Risk of Physical Multimorbidity and Disability in Midlife
  • Youth with Histories of Out-of-Home Placement Face Significantly Longer Emergency Department Stays and Higher Restraint Rates During Mental Health Crises
  • Dose-Response Risk: How Multiple Maternal Chronic Conditions Shape Neonatal Morbidity and Mortality
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in